SAN FRANCISCO, Jan. 29, 2014 /PRNewswire/ -- Medizone
International, Inc. (The Company) (MZEI:OB, MZEI:QB) has just been
granted its fourth patent for its revolutionary enclosed space room
disinfection system, AsepticSure. The United States Patent
and Trademark Office has issued US Patent number 8,636,951 titled
BIO-TERRORISM COUNTERACTION USING OZONE AND HYDROGEN
PEROXIDE.
Following on the heels of patent protection being established
for its health care related patent applications, the Company has
now been awarded a patent for its government variant of AsepticSure
intended for use by defense agencies as a response to a biological
attack on critical buildings, infrastructure and resources.
Dr. Michael E. Shannon, Medizone
International's President explained, "At our Innovation Park,
Queens University laboratories, we have
been successful in completely eliminating Bacillus atropheus and
Bacillus subtilis, both internationally recognized study surrogates
for Anthrax, one of the most difficult weaponized pathogens to
kill. Being able to eliminate these surrogates for Anthrax
with our technology almost assures we now have the ability to
remediate critical public infrastructure following a biological
attack and restore it to service without damaging important and
expensive equipment including communications systems.
Militaries have struggled with this problem for decades and, until
now, this simply has not been possible."
"To now have patent protection granted for this system," stated
Edwin Marshall, Medizone's CEO,
"should allow the Company protected access to a potentially
lucrative government market due to the unique capability of
AsepticSure's government variant."
This Press Release may contain certain forward looking
statements that could involve substantial risks and uncertainties,
including, but not limited to, the results of ongoing clinical
studies, economic conditions, product and technology development,
production efficiencies, product demand, competitive products,
competitive environment, successful testing and government
regulatory issues. Additional risks are identified in the company's
filings made with the Securities and Exchange Commission.
For Medizone International Inc. Investor inquiries, please
contact:
John Pentony, Investor
Relations
T: (415) 331-0202
E: j.pentony@medizoneint.com
For Medizone International Inc. Media inquiries, please
contact:
Gary Hanauer, Media Contact
T: (510) 686-1238
E: GarHan@aol.com
For more information, visit:
http://www.medizoneint.com
Email: operations@medizoneint.com
SOURCE Medizone International, Inc.